Moderna is suing Pfizer and BioNTech for infringing patents central to Moderna's mRNA technology platform used to develop the COVID vaccine, the company said in a press release Friday. A widely ...
With COVID vaccine sales in the doldrums and a respiratory syncytial virus (RSV) vaccine market in “contraction”, Moderna CEO Stéphane Bancel had the unenviable task of trying to put a positive spin ...
Moderna on Thursday said it plans to slash roughly 10% of its global workforce by the end of the year, as Covid shot sales continue to dwindle and the company grapples with uncertainty in the vaccine ...
Mast interviewed more than two dozen former and current Moderna employees, along with analysts, rival executives, investors, and experts in mRNA and vaccines to understand how the company arrived at ...
Moderna, Inc. plans to cut $1.1bn in costs by 2027, pausing and scrapping several R&D programs, leading to a pre-market stock drop of over 13%. Despite pledging 10 product approvals by 2027, falling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback